SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Parsons James T.

(Last)

(First)

(Middle)

C/O TRILLIUM THERAPEUTICS INC.

2488 DUNWIN DRIVE

(Street)

MISSISSAUGA

L5L 1J9

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2021

3. Issuer Name and Ticker or Trading Symbol
Trillium Therapeutics Inc. [ TRIL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	12/23/2030	Common Shares	180,000	$12.03	D
Stock Option (Right to Buy)	⁽¹⁾	11/07/2029	Common Shares	94,792	$0.3002⁽³⁾	D
Stock Option (Right to Buy)	⁽¹⁾	11/08/2028	Common Shares	59,896	$3.3417⁽⁴⁾	D
Stock Option (Right to Buy)	⁽¹⁾	11/26/2026	Common Shares	14,266	$7.268⁽⁵⁾	D
Stock Option (Right to Buy)	⁽²⁾	04/17/2024	Common Shares	36,204	$8.1765⁽⁶⁾	D
Stock Option (Right to Buy)	⁽¹⁾	11/09/2027	Common Shares	24,390	$9.6538⁽⁷⁾	D
Stock Option (Right to Buy)	⁽¹⁾	05/27/2026	Common Shares	30,171	$11.0442⁽⁸⁾	D
Stock Option (Right to Buy)	⁽¹⁾	11/19/2025	Common Shares	30,171	$15.2731⁽⁹⁾	D

Explanation of Responses:

1. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.

2. 1/3 of the options vested immediately upon grant and the remaining options vest in equal annual installments over the following four years.

3. The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

4. The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

5. The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

6. The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

7. The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

8. The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

9. The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

	/s/ James Parsons	01/04/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.